Alvotech Completes Private Placement to Boost Shareholder Base

Alvotech ( (ALVO) ) has shared an update.

On June 11, 2025, Alvotech announced the completion of a private placement conducted on June 4, 2025, involving the transfer of shares and Swedish Depositary Receipts (SDRs) to institutional investors. The placement attracted about 40 institutional investors, with a significant portion of demand from Sweden, Norway, the UK, and the US. This move is expected to diversify and strengthen Alvotech’s shareholder base, increase the free float of SDRs on Nasdaq Stockholm, and enhance the company’s position in the biosimilars market.

The most recent analyst rating on (ALVO) stock is a Hold with a $14.00 price target. To see the full list of analyst forecasts on Alvotech stock, see the ALVO Stock Forecast page.

Spark’s Take on ALVO Stock

According to Spark, TipRanks’ AI Analyst, ALVO is a Neutral.

Alvotech’s strong earnings call and product pipeline are promising, but financial instability and high leverage pose significant risks. The technical analysis provides a moderately positive outlook, while the high P/E ratio indicates market optimism. Addressing financial challenges is crucial for sustained growth.

To see Spark’s full report on ALVO stock, click here.

More about Alvotech

Alvotech is a global biotech company specializing in the development and manufacture of biosimilar medicines. The company aims to be a leader in the biosimilar industry by providing high-quality, cost-effective products and services. Alvotech has a diverse pipeline targeting autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer, and has formed strategic partnerships to expand its global reach.

Average Trading Volume: 192,830

Technical Sentiment Signal: Sell

Current Market Cap: $3.13B

For detailed information about ALVO stock, go to TipRanks’ Stock Analysis page.